Lifethreatening anaphylactic reactions to muscle-relaxant drugs pose a problem of concern to anaesthetists. Indeed alcuronium, the most commonly used muscle relaxant in Australia, was temporarily withdrawn in South Australia a few years ago because of such reactions. The introduction of the new muscle relaxant, atracurium, into Australia has been made conditional on surveillance to determine the incidence of anaphylactoid reactions. With the imminent introduction of another new muscle relaxant, vecuronium, and the recent reports of anaphylactoid reactions to both drugs, t.2.3 the question of the likelihood of the newer muscle relaxants producing severe reactions is relevant. Both drugs release minimal histamine when given intravenously,4 although atracurium is a potent cutaneous histamine releaser. 5 However, the ability of a drug to produce severe reactions does not correlate with its direct histamine-releasing effects. 6 The limited figures that are available suggest that the incidence of reactions to a particular muscle relaxant is related to the amount of relaxant used,7.8 with the exception of pancuronium which appears inherently safer than others. 7 . 8 • 9 Thus as the use of a muscle relaxant increases the incidence of reactions to it should increase.
What of the role of atracurium and vecuronium in patients with previous reactions to other muscle relaxants? Because the reports of reactions to the new muscle relaxants are sparse and because the patients cannot have received the drugs previously, it is tempting to advocate a possible role for new muscle relaxants. However, at least 50070 of patients who react to one muscle relaxant will be sensitive to one or more others, and the cross-sensitivity does not follow predictable patterns. lO . tt Skin testing data from France suggest patients allergic to pancuronium will be allergic to vecuronium, t2 and data from Anaesthesia (In(/ l!llen':Jil'(~ Curl', Vol. 14, No. I, FehrllllTl". 1986 New Zealand suggest that pancuronium, vecuronium and atracurium are likely to show cross-sensitivity.t3 One case has been reported of a patient who reacted to both vecuronium and pancuronium,2 and one patient who reacted to vecuronium showed cutaneous sensitivity to vecuronium and alcuronium. 3 Radioimmunoassay studies in this unit in Australian patients who had previously had anaphylactic reactions to muscle relaxants demonstrated relaxant-specific IgE antibodies which bound with metocurine, vecuronium, fazadinium, and atracurium. These drugs the patients could not have received previously, but would certainly have produced reactions if administered. t4 The antigenic group on muscle relaxants is the quaternary or tertiary ammonium group.t5
These groups, also confer neuromuscular-blocking properties upon the drugs and their distance apart (0.6-1.4 nm) is appropriate to bridge IgE molecules and produce anaphylactic reactions. Thus the likelihood of producing anaphylactic reactions, particularly in patients with a previous history of anaphylaxis to muscle relaxants, appears to be an inevitable consequence of their structure.
Newer muscle relaxants should therefore be used in patients with known sensitivity to muscle relaxants only after appropriate skin testing. Even then the options of pretreatment or nonrelaxant anaesthetic techniques should be considered.
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